Efficacy of incobotulinumtoxinA for Spasticity-Associated Pain in a Series of Patients with Spasticity of Diverse Etiologies

Background: Spasticity is a motor disorder that appears as cause of upper and lower limb disability, frequently causing pain. IncobotulinumtoxinA (IncoA) has proved effective for treating diverse musculoskeletal pathologies, including spasticity spasticity-related Aims: The aim was to determine the efficacy IncoA treatment pain associated etiologies. Methods: Prospective, single-center study 30 patients treated with between May August 2021 at University Hospital Center Central Lisbon (Lisbon, Portugal). Primary endpoint improvement in pain, assessed by employing numerical rating scale baseline 12 weeks post-injection, scoring 0 (no pain) 10 (severe pain). Results: Patients showed due different etiologies, mainly ischemic stroke (46.7%), hemorrhagic (23.3%) cerebral palsy (20.0%). Mean score significantly decreased from (mean: 6.8, range: 2-10) post-injection 1.6; 0-5). reduction -5.2 points (95%CI: -5.9, -4.5). All achieved minimum clinically significant difference reduction, showing sustained effect over regardless etiology. Conclusion: may be considered an alternative spasticity-associated etiologies limbs.